The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer

Lung Cancer

Volumn 79, Issue 3, 2013, Pages 312-317

  Nygaard, Anneli Dowler ^a   Garm Spindler, Karen Lise ^a   Pallisgaard, Niels ^a   Andersen, Rikke Fredslund ^a   Jakobsen, Anders ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

Author keywords

EGF system; KRAS mutation; Non small cell lung cancer; NSCLC; Plasma KRAS; Prognostic marker

Indexed keywords

CARBOPLATIN; K RAS PROTEIN; NAVELBINE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TUMOR MARKERS, BIOLOGICAL; VINBLASTINE;

EID: 84873207633     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.11.016     Document Type: Article

References (20)

1. Araujo A., Ribeiro R., Azevedo I., Coelho A., Soares M., Sousa B., et al. Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer-a review of the literature. Oncologist 2007, 12:201-210.
2. De R.W., Claes B., Bernasconi D., De S.J., Biesmans B., Fountzilas G., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11:753-762.
3. Langer C.J. Roles of EGFR and KRAS mutations in the treatment of patients with non-small-cell lung cancer. Pharm Ther 2011, 36:263-279.
4. Douillard J.Y., Shepherd F.A., Hirsh V., Mok T., Socinski M.A., Gervais R., et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 2010, 28:744-752.
5. Fukuoka M., Wu Y.L., Thongprasert S., Sunpaweravong P., Leong S.S., Sriuranpong V., et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011, 29:2866-2874.
6. Mao C., Qiu L.X., Liao R.Y., Du F.B., Ding H., Yang W.C., et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer 2010, 69:272-278.
7. Mascaux C., Iannino N., Martin B., Paesmans M., Berghmans T., Dusart M., et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005, 92:131-139.
8. Spindler K.L., Pallisgaard N., Vogelius I., Jakobsen A. Quantitative cell-free DNA, KRAS and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res 2012, 18:1177-1185.
9. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
10. Garm Spindler K.L., Pallisgaard N., Rasmussen A.A., Lindebjerg J., Andersen R.F., Cruger D., et al. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer. Ann Oncol 2009, 20:879-884.
11. Wang S., An T., Wang J., Zhao J., Wang Z., Zhuo M. Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer. Clin Cancer Res 2010, 16:1324-1330.
12. Camps C., Jantus-Lewintre E., Cabrera A., Blasco A., Sanmartin E., Gallach S., et al. The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients. Lung Cancer 2011, 72:365-369.
13. Gautschi O., Huegli B., Ziegler A., Gugger M., Heighway J., Ratschiller D., et al. Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Lett 2007, 254:265-273.
14. Boldrini L., Ali G., Gisfredi S., Ursino S., Baldini E., Melfi F., et al. Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study. Oncol Rep 2009, 22:683-691.
15. Massarelli E., Varella-Garcia M., Tang X., Xavier A.C., Ozburn N.C., Liu D.D., et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007, 13:2890-2896.
16. viel-Ronen S., Blackhall F.H., Shepherd F.A., Tsao M.S. K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer 2006, 8:30-38.
17. Cortot A.B., Italiano A., Burel-Vandenbos F., Martel-Planche G., Hainaut P. KRAS mutation status in primary nonsmall cell lung cancer and matched metastases. Cancer 2010, 116:2682-2687.
18. Kalikaki A., Koutsopoulos A., Trypaki M., Souglakos J., Stathopoulos E., Georgoulias V., et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer 2008, 99:923-929.
19. Custodio A.B., Gonzalez-Larriba J.L., Bobokova J., Calles A., Alvarez R., Cuadrado E., et al. Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer. J Thorac Oncol 2009, 4:891-910.
20. Kalikaki A., Koutsopoulos A., Hatzidaki D., Trypaki M., Kontopodis E., Stathopoulos E., et al. Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer 2010, 69:110-115.